ORI goes oncolytic

Why ORI is backing oncolytic virus company Cold Genesys

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer.

ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold Genesys Inc. since 2015 and was impressed

Read the full 415 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE